At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 14,075 enrolled
Drug / intervention
COA566drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Cluster Randomized, Single-centre, Controlled, Parallel,12-month Prospective Study and Additional 12-month Follow-up in Africa of Malaria Incidence in a Community Setting Following Systematic Treatment of P. Falciparum Asymptomatic Carriers With Artemether-lumefantrine (Coartem® / Coartem® Dispersible)
In Brief
A Phase 4 clinical trial evaluating COA566 for Malaria. Completed, enrolled 14,075 participants across 3 sites.
Detailed Summary
This study assessed the impact of the systematic detection by Rapid Diagnostic Test (RDT) and treatment of asymptomatic carriers of malaria parasites (P. falciparum) with COA566 on a number of clinical malaria cases in children less than 5 years of age and the improvement of hemoglobin levels in the overall population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesBurkina Faso
Collaborators--
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartNov 2010
First PostedDec 2010
Primary CompletionJul 2012
TodayJul 2026
First PostedDec 8, 2010
Enrollment StartNov 1, 2010
Primary CompletionJul 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.7 yearsPosted 15.6 years ago
Interventions
COA566drug
COA566 tablets or dispersible tablets twice daily during 3 days; dosage according to body weight.